Various studies evaluated CSF BAFF/APRIL levels in MS, measured through ELISA or Luminex assays, without conclusive results, even though it is worth noting that these methodologies may lack the sensitivity required to detect subtle changes in biomarker levels. Here, TNFSF13 is linked to myeloid sarcoma.